Reimbursed Care Access in Lesotho

Currently classified as a strictly controlled substance under Lesotho’s national Drugs of Abuse Act (2008), and listed among prohibited psychotropic substances (psilocine/psilocybin appear in the Act’s schedules). There is no authorised medical/reimbursement pathway for psilocybin outside of approved clinical research; possession, supply and unauthorised importation are criminalised under the Act. #

Currently classified as a strictly controlled substance under Lesotho’s Drugs of Abuse Act (2008) and explicitly appears in the list of controlled psychotropic substances; there is no authorised medical or reimbursed access for MDMA outside of approved clinical research. Standardised national policy treats MDMA-related activity as criminal unless conducted under an approved research licence. #

There is no publicly available evidence of a national marketing authorisation or funded reimbursement pathway for esketamine (Spravato) in Lesotho; regulation of medicines and controlled substances is overseen by the Ministry of Health, which manages licences, import permits and controlled‑drug regulation for medicinal products. As a result, routine reimbursed access to esketamine for treatment‑resistant depression is not established in Lesotho and any access would depend on an import licence, special authorisation, or participation in an authorised clinical trial. For context, esketamine has been authorised and reimbursed in some higher‑income jurisdictions under restricted programmes (e.g., EMA/US approvals), but those authorisations do not imply availability in Lesotho absent national registration. #; #

Ketamine is a recognised and routinely used anaesthetic and analgesic agent in clinical practice globally, and in Lesotho its use as an anaesthetic and for procedural sedation falls under normal medicines regulation and hospital practice overseen by the Ministry of Health and facility licensing authorities; national regulation covers controlled substances, importation and storage requirements. Licensing and supply of medicines (including controlled anaesthetics) is regulated through MoH pathways for importation, hospital formularies and professional oversight, so ketamine is available for essential surgical and emergency care when procured by hospitals or clinics. However, ketamine’s use specifically as a reimbursed psychiatric intervention (e.g., repeated IV ketamine infusion for depression) is not established as a funded, nationwide reimbursed treatment program in Lesotho — such psychiatric uses would generally be off‑label, provided at clinician discretion in private settings (if available), and subject to hospital policy, clinician credentialing, and narcotics/psychotropic handling rules. Guidance from international clinical authorities (and operational guidance used by humanitarian/clinical providers) outlines safe clinical administration conditions and the need for monitoring and appropriate facilities. #; #

Currently classified as a strictly controlled substance under Lesotho’s Drugs of Abuse Act (2008) (DMT is treated among scheduled psychotropic compounds under international/ national lists). There is no authorised medical or reimbursed access for DMT outside of approved clinical research, and activities involving DMT (possession, supply, import/export) are regulated and criminalised unless performed under an authorised research licence. #

Currently classified as a strictly controlled substance under national drug scheduling laws (covered by broad psychotropic/analogues provisions in the Drugs of Abuse Act, 2008), with no authorised medical use or reimbursed access outside of approved clinical research. Practically, 5‑MeO‑DMT is treated the same as other novel tryptamines under national controlled‑substance controls. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Lesotho’s statutory schedules do not provide an established medical/reimbursed pathway for ibogaine and any importation or clinical use would require explicit regulatory approval and licensing. #

The principal psychoactive component of ayahuasca (DMT) is a scheduled psychotropic under Lesotho’s Drugs of Abuse Act (2008); accordingly, ayahuasca brews containing DMT are effectively subject to the same controls. At the international level plants and traditional preparations occupy a legal grey area in many jurisdictions, but under Lesotho law the presence of a scheduled active compound (DMT) subjects the preparation to control—there is no authorised medical or reimbursed access outside approved research. #; #

Mescaline is explicitly listed among scheduled psychotropic substances under Lesotho’s Drugs of Abuse Act (2008) and therefore is controlled with no established medical/reimbursed access outside authorised clinical research. Activities involving mescaline (possession, distribution, importation) are subject to criminal penalties unless performed under a regulatory research exemption. #

Currently classified as a strictly controlled substance under Lesotho’s national drug schedules (the Drugs of Abuse Act enumerates many substituted phenethylamines and covers analogues/derivatives), with no authorised medical use outside of approved clinical research. There is no pathway for reimbursement or routine clinical provision of 2C‑series compounds in Lesotho. #